Syndax Pharmaceuticals Inc

Explore Syndax Pharmaceuticals’ cancer‑drug promise amid a turbulent stock‑price and negative P/E ratio, uncovering its financial challenges and investor sentiment.

Explore how Syndax’s new inducement grants under NASDAQ Rule 5635(c)(4) drive employee incentives, boost investor confidence, and impact the SNDX stock price.

Discover how Syndax Pharmaceuticals is reshaping oncology with cutting‑edge cancer therapies, strong Nasdaq performance, and a focus on patient‑centered innovation.

Explore Syndax Pharmaceuticals (SYND) – a biotech trailblazer developing cancer therapies amid volatile stock swings, promising high‑potential growth.

Explore Syndax Pharmaceuticals’ role in oncology innovation, its Nasdaq-listed stock dynamics, and future cancer therapy prospects.

Explore Syndax Pharmaceuticals: a biotech firm targeting solid tumors & cancers with high‑risk, high‑reward stock dynamics and a hopeful pipeline for breakthrough therapies.

Explore Syndax Pharmaceuticals: a biotech leader developing innovative solid‑tumor, lung, breast, and blood‑cancer therapies amid volatile stock swings and growth potential.

Syndax Pharmaceuticals, a biotechnology company, has made significant strides in developing cancer therapies, with a market capitalization of $1.15 billion and a stock price of $13.11 as of October 26, 2025.

Syndax Pharmaceuticals, a biopharmaceutical company, continues to focus on developing therapies for solid tumors and various cancers, with a market capitalization of $1.33 billion and a stock price of $14.3 as of October 16, 2025.

Syndax Pharmaceuticals is set to release its quarterly financial results on August 4, 2025, with analysts expecting a significant revenue surge and a loss per share of -1.016 USD.